Standards of care for anemia management in oncology: focus on lung carcinoma.

摘要: BACKGROUND Anemia is common in patients with lung carcinoma, particularly among those undergoing platinum-based cytotoxic chemotherapy. Evidence growing that anemia can have a profound impact on the patient's quality of life, often manifested as inability to function normally. METHODS A literature review was conducted provide current picture incidence and carcinoma usage limitations treatment. RESULTS The (a hemoglobin [Hb] level < 11g/dL) approximately 50–60%, varying according treatment regimen. However, despite evidence supporting anemia, many clinicians only intervene when Hb levels fall below 8 g/dL. This may be because lack awareness cancer patients, but most likely options (blood transfusion recombinant human erythropoietin [epoetin-α]). Darbepoetin-α represents new generation erythropoiesis-stimulating proteins. Biochemically distinct from epoetin-α, darbepoetin-α has greater sialic acid content biologic half-life than stimulates erythropoiesis same manner. Clinical trials involving cancer-related shown threefold longer which allow less frequent dosing. The results an ongoing clinical trial dedicated testing benefits treating will valuable insight into its full potential this setting. CONCLUSIONS Anemia reported undertreated carcinoma. introduction practice overcome some treatments facilitate improvement management anemia. Cancer 2002;95:613–23. © 2002 American Society. DOI 10.1002/cncr.10712